Bevacizumab’s similar efficacy compared with ranibizumab and its 40-fold lower wholesale cost has prompted several comparative efficacy studies. Table 4-4 summarizes the major studies comparing bevacizumab to ranibizumab efficacy in the management of neovascular AMD.